ArticleScientific reports2017
T cells upon activation promote endothelin 1 production in monocytes via IFN-γ and TNF-α.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- Network Pharmacology-Based Exploration of Complementary Molecular Mechanisms of Heat-Clearing (Scutellariae Radix, Coptidis Rhizoma) and Blood-Tonifying Herbs (Angelicae Sinensis Radix, Paeoniae Radix Alba) in Cold Hypersensitivity in Hands and Feet.Life (Basel, Switzerland) · 2026Article
- Interferon-γ and interleukin-17A associations with vascular dysfunction following paediatric cardiac surgery with cardiopulmonary bypass.Cardiology in the young · 2026Article
- Neuronal Endothelin a Receptor Mediates Experimental and Clinical Vascular Pain through an Endothelial-Neural Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Endothelin antagonists for hypertension: has their time finally arrived?Clinical science (London, England : 1979) · 2025Review
- Endothelin Receptor Antagonists for the Treatment of Hypertension: Recent Data from Clinical Trials and Implementation Approach.Current cardiology reports · 2025Review
- Endothelin-1 signaling in the kidney: recent advances and remaining gaps.American journal of physiology. Renal physiology · 2025Review
- Gut microbiota deficiency reduces neutrophil activation and is protective after ischemic stroke.Journal of neuroinflammation · 2025Article
- Polymorphism-driven immune disruptions in Kawasaki disease across populations: decoding the role of T and B-cells.Frontiers in immunology · 2025Review
- The human milk oligosaccharide 3'sialyllactose reduces low-grade inflammation and atherosclerosis development in mice.JCI insight · 2024Article
- Article
- Endothelin System in Hypertension and Chronic Kidney Disease.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Article
- Pharmacogenomics of intravenous immunoglobulin response in Kawasaki disease.Frontiers in immunology · 2023Article
- Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse.Seminars in cancer biology · 2022Review
- Article
- Modeling of endothelial cell dysfunction using human induced pluripotent stem cells derived from patients with end-stage renal disease.Kidney research and clinical practice · 2021Article
- Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine.The EPMA journal · 2021Review
- Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.Pulmonary pharmacology & therapeutics · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelin 1 (ET-1), mainly produced from vascular endothelial cells, induces vasoconstriction in physiological conditions. The endothelin receptor antagonist is among the most effective agents for pulmonary hypertension. However, little is known about the production source of ET-1 in inflammation and immunity. Here, we studied whether T cell-mediated ET-1 production system exists and operates independent of the production system in vascular endothelial cells. ET-1 production was readily detectable in the culture supernatant of human PBMCs and murine spleen cells stimulated with anti-CD3 antibody. Immunocytostaining showed that ET-1-producing cells emerged only in PBMCs stimulated with anti-CD3 antibody. Using the Transwell system, both murine and human monocytes sorted with magnetic beads in the inner chamber produced ET-1 when T cells were activated with antigen or anti-CD3 antibody in the outer chamber. This ET-1 production was inhibited by anti-IFN-γ and/or TNF-α antibody. Furthermore, monocytes purified from ET
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.